Scholarlink

Background <p>Despite the high global incidence of asthma and atrial fibrillation (AF), the causal relationship between the two conditions remains unclear. Emerging observational evidence suggests a potential association; however, conflicting results and limited mechanistic insights necessitate a comprehensive evaluation. This study aims to determine the causal relationship between asthma and the risk of AF and to explore the underlying molecular mechanisms.</p> Methods <p>We performed a meta-analysis of observational studies to assess the association between asthma and AF risk, followed by a two-sample Mendelian randomization (MR) analysis to infer causality. Bioinformatics analyses using data from the Gene Expression Omnibus (GEO) were conducted to identify differentially expressed genes (DEGs) and enriched pathways. Potential therapeutic targets were validated through drug-gene interaction screening.</p> Results <p>The meta-analysis of eight observational studies involving 1,067,774 participants demonstrated that asthma was associated with a 21% increased risk of AF (odds ratio (OR) = 1.21, 95% confidence interval (CI): 1.07–1.36, <i>p</i> = 0.003). Two-sample MR analyses of European populations revealed that genetically predicted asthma was causally associated with increased AF risk (inverse-variance weighted (IVW) OR = 1.001, 95% CI: 1.000-1.002, <i>p</i> = 0.019), whereas no significant association was observed in East Asian cohorts. Transcriptomic analyses identified carboxypeptidase A3 (CPA3) as a shared upregulated gene in both asthma and AF, potentially involved in renin-angiotensin system dysregulation. Drug-gene interaction screening suggested osilodrostat and metyrapone as potential therapeutic candidates targeting CPA3.</p> Conclusions <p>Our study provides evidence that genetic predisposition to asthma is significantly associated with an increased risk of AF in the European population. Transcriptomic data analyses suggest that CPA3 and its interactions with therapeutic drugs could serve as potential biomarkers, offering new opportunities to improve prognosis in patients with coexisting asthma and AF.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Asthma increased the risk of atrial fibrillation: insights from clinical association to genetic and molecular evidence

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Yan Zheng,
  • Yanzhen Zhu,
  • Jiayi Feng,
  • Jianping Hu,
  • Zhenhong Jiang,
  • Jin Ouyang,
  • Huitian Liao,
  • Hong Deng,
  • Wenfeng He,
  • Yang Shen

摘要

Background

Despite the high global incidence of asthma and atrial fibrillation (AF), the causal relationship between the two conditions remains unclear. Emerging observational evidence suggests a potential association; however, conflicting results and limited mechanistic insights necessitate a comprehensive evaluation. This study aims to determine the causal relationship between asthma and the risk of AF and to explore the underlying molecular mechanisms.

Methods

We performed a meta-analysis of observational studies to assess the association between asthma and AF risk, followed by a two-sample Mendelian randomization (MR) analysis to infer causality. Bioinformatics analyses using data from the Gene Expression Omnibus (GEO) were conducted to identify differentially expressed genes (DEGs) and enriched pathways. Potential therapeutic targets were validated through drug-gene interaction screening.

Results

The meta-analysis of eight observational studies involving 1,067,774 participants demonstrated that asthma was associated with a 21% increased risk of AF (odds ratio (OR) = 1.21, 95% confidence interval (CI): 1.07–1.36, p = 0.003). Two-sample MR analyses of European populations revealed that genetically predicted asthma was causally associated with increased AF risk (inverse-variance weighted (IVW) OR = 1.001, 95% CI: 1.000-1.002, p = 0.019), whereas no significant association was observed in East Asian cohorts. Transcriptomic analyses identified carboxypeptidase A3 (CPA3) as a shared upregulated gene in both asthma and AF, potentially involved in renin-angiotensin system dysregulation. Drug-gene interaction screening suggested osilodrostat and metyrapone as potential therapeutic candidates targeting CPA3.

Conclusions

Our study provides evidence that genetic predisposition to asthma is significantly associated with an increased risk of AF in the European population. Transcriptomic data analyses suggest that CPA3 and its interactions with therapeutic drugs could serve as potential biomarkers, offering new opportunities to improve prognosis in patients with coexisting asthma and AF.